The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$23.42 ...

Your friends are going to be a little miffed when you emotionally replace them with this NeeDoh gummy bear and this ...

Here are 201+ Black-owned businesses to shop during Black History Month and beyond. Shop Telfar, Jungalow, Pattern Beauty, ...

Johnson and her husband Andrew East’s partnership with Beam Kids came to fruition after the couple struggled to find the best ways to ensure their children got the vitamins, probiotics and greens they ...

Kenvue shows decent growth but struggles with profitability. Find out why KVUE stock is a 'hold' as cost-cutting efforts face ...

Natural Cycles uses a proprietary algorithm and daily body temperature readings to track ovulation and identify fertile ...

Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...

Johnson & Johnson (JNJ) faces a $1B+ reimbursement demand for cancer cases linked to talc products. Read more here.

Robert F. Kennedy Jr’s confirmation hearings began Wednesday before the Senate Finance Committee. He appears before the ...

Johnson & Johnson (NYSE:JNJ) is a major player in the healthcare industry, with a portfolio that includes pharmaceuticals, Medtech devices, and consumer health products. The company is known for ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system. Johnson & Johnson recently concentrated on fostering innovations within its segments ...